Enzyvant Therapeutics

Rachelle Jacques, CEO

Oct. 13 | 2:15pm | BlueRock Therapeutics Ballroom

Cambridge, MA


In-person Presentation

Enzyvant Therapeutics is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant’s lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the U.S. Food and Drug Administration designation as a Regenerative Medicine Advanced Therapy. Enzyvant is part of Sumitovant Biopharma, a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the U.S., China, and the EU as well as talent, knowledge, and resources across a wide spectrum of technologies and therapeutic areas.


By using this website you agree to accept our Privacy Policy and Terms & Conditions